Strategies to manage hepatitis C virus (HCV) disease burden.

H. Wedemeyer; A. S. Duberg; M. Buti; W. M. Rosenberg; S. Frankova; G. Esmat; N. Örmeci; Vlierberghe H Van; M. Gschwantler; U. Akarca; S. Aleman; I. Balık; T. Berg; F. Bihl; M. Bilodeau; A. J. Blasco; Mello CE Brandão; P. Bruggmann; F. Calinas; J. L. Calleja; H. Cheinquer; P. B. Christensen; M. Clausen; H. S.M. Coelho; M. Cornberg; M. E. Cramp; G. J. Dore; W. Doss; M. H. El-Sayed; G. Ergör; C. Estes; K. Falconer; J. Félix; M. L.G. Ferraz; P. R. Ferreira; J. García-Samaniego; J. Gerstoft; J. A. Giria; F. L. Gonçales; Pessôa M Guimarães; C. Hézode; S. J. Hindman; H. Hofer; P. Husa; R. Idilman; M. Kåberg; K. D.E. Kaita; A. Kautz; S. Kaymakoglu; M. Krajden; H. Krarup; W. Laleman; D. Lavanchy; P. Lázaro; R. T. Marinho; P. Marotta; S. Mauss; Correa MC Mendes; C. Moreno; B. Müllhaupt; R. P. Myers; V. Nemecek; A. L.H. Øvrehus; J. Parkes; K. M. Peltekian; A. Ramji; H. Razavi; N. Reis; S. K. Roberts; F. Roudot-Thoraval; S. D. Ryder; R. Sarmento-Castro; C. Sarrazin; D. Semela; M. Sherman; G. E. Shiha; J. Sperl; P. Stärkel; R. E. Stauber; A. J. Thompson; P. Urbanek; Damme P Van; Thiel I van; D. Vandijck; W. Vogel; I. Waked; null Wei

doi:10.1111/jvh.12249

Strategies to manage hepatitis C virus (HCV) disease burden.

H. Wedemeyer, A. S. Duberg, M. Buti, W. M. Rosenberg, S. Frankova, G. Esmat, N. Örmeci, Vlierberghe H Van, M. Gschwantler, U. Akarca, S. Aleman, I. Balık, T. Berg, F. Bihl, M. Bilodeau, A. J. Blasco, Mello CE Brandão, P. Bruggmann, F. Calinas, J. L. CallejaH. Cheinquer, P. B. Christensen, M. Clausen, H. S.M. Coelho, M. Cornberg, M. E. Cramp, G. J. Dore, W. Doss, M. H. El-Sayed, G. Ergör, C. Estes, K. Falconer, J. Félix, M. L.G. Ferraz, P. R. Ferreira, J. García-Samaniego, J. Gerstoft, J. A. Giria, F. L. Gonçales, Pessôa M Guimarães, C. Hézode, S. J. Hindman, H. Hofer, P. Husa, R. Idilman, M. Kåberg, K. D.E. Kaita, A. Kautz, S. Kaymakoglu, M. Krajden, H. Krarup, W. Laleman, D. Lavanchy, P. Lázaro, R. T. Marinho, P. Marotta, S. Mauss, Correa MC Mendes, C. Moreno, B. Müllhaupt, R. P. Myers, V. Nemecek, A. L.H. Øvrehus, J. Parkes, K. M. Peltekian, A. Ramji, H. Razavi, N. Reis, S. K. Roberts, F. Roudot-Thoraval, S. D. Ryder, R. Sarmento-Castro, C. Sarrazin, D. Semela, M. Sherman, G. E. Shiha, J. Sperl, P. Stärkel, R. E. Stauber, A. J. Thompson, P. Urbanek, Damme P Van, Thiel I van, D. Vandijck, W. Vogel, I. Waked, Wei

Peninsula Medical School

Hannover Medical School

Research output: Contribution to journal › Article › peer-review

Abstract

The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.

Original language	English
Pages (from-to)	60-89
Number of pages	0
Journal	J Viral Hepat
Volume	0
Issue number	0
DOIs	https://doi.org/10.1111/jvh.12249
Publication status	Published - May 2014

Keywords

HCV
diagnosis
disease burden
epidemiology
hepatitis C
incidence
mortality
prevalence
scenarios
treatment
Adolescent
Adult
Aged
80 and over
Antiviral Agents
Diagnostic Tests
Routine
Disease Eradication
Drug Therapy
Combination
Female
Global Health
Hepatitis C
Chronic
Humans
Incidence
Male
Middle Aged
Models
Statistical
Prevalence
Young Adult

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jvh.12249

Cite this

Wedemeyer, H., Duberg, A. S., Buti, M., Rosenberg, W. M., Frankova, S., Esmat, G., Örmeci, N., Van, V. H., Gschwantler, M., Akarca, U., Aleman, S., Balık, I., Berg, T., Bihl, F., Bilodeau, M., Blasco, A. J., Brandão, M. CE., Bruggmann, P., Calinas, F., ... Wei (2014). Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat, 0(0), 60-89. https://doi.org/10.1111/jvh.12249

@article{06c281e507bb46c6a94aa3b422b1266f,

title = "Strategies to manage hepatitis C virus (HCV) disease burden.",

abstract = "The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.",

keywords = "HCV, diagnosis, disease burden, epidemiology, hepatitis C, incidence, mortality, prevalence, scenarios, treatment, Adolescent, Adult, Aged, 80 and over, Antiviral Agents, Diagnostic Tests, Routine, Disease Eradication, Drug Therapy, Combination, Female, Global Health, Hepatitis C, Chronic, Humans, Incidence, Male, Middle Aged, Models, Statistical, Prevalence, Young Adult",

author = "H. Wedemeyer and Duberg, {A. S.} and M. Buti and Rosenberg, {W. M.} and S. Frankova and G. Esmat and N. {\"O}rmeci and Van, {Vlierberghe H} and M. Gschwantler and U. Akarca and S. Aleman and I. Balık and T. Berg and F. Bihl and M. Bilodeau and Blasco, {A. J.} and Brand{\~a}o, {Mello CE} and P. Bruggmann and F. Calinas and Calleja, {J. L.} and H. Cheinquer and Christensen, {P. B.} and M. Clausen and Coelho, {H. S.M.} and M. Cornberg and Cramp, {M. E.} and Dore, {G. J.} and W. Doss and El-Sayed, {M. H.} and G. Erg{\"o}r and C. Estes and K. Falconer and J. F{\'e}lix and Ferraz, {M. L.G.} and Ferreira, {P. R.} and J. Garc{\'i}a-Samaniego and J. Gerstoft and Giria, {J. A.} and Gon{\c c}ales, {F. L.} and Guimar{\~a}es, {Pess{\^o}a M} and C. H{\'e}zode and Hindman, {S. J.} and H. Hofer and P. Husa and R. Idilman and M. K{\aa}berg and Kaita, {K. D.E.} and A. Kautz and S. Kaymakoglu and M. Krajden and H. Krarup and W. Laleman and D. Lavanchy and P. L{\'a}zaro and Marinho, {R. T.} and P. Marotta and S. Mauss and Mendes, {Correa MC} and C. Moreno and B. M{\"u}llhaupt and Myers, {R. P.} and V. Nemecek and {\O}vrehus, {A. L.H.} and J. Parkes and Peltekian, {K. M.} and A. Ramji and H. Razavi and N. Reis and Roberts, {S. K.} and F. Roudot-Thoraval and Ryder, {S. D.} and R. Sarmento-Castro and C. Sarrazin and D. Semela and M. Sherman and Shiha, {G. E.} and J. Sperl and P. St{\"a}rkel and Stauber, {R. E.} and Thompson, {A. J.} and P. Urbanek and Van, {Damme P} and van, {Thiel I} and D. Vandijck and W. Vogel and I. Waked and Wei",

year = "2014",

month = may,

doi = "10.1111/jvh.12249",

language = "English",

volume = "0",

pages = "60--89",

journal = "J Viral Hepat",

issn = "1365-2893",

number = "0",

}

Wedemeyer, H, Duberg, AS, Buti, M, Rosenberg, WM, Frankova, S, Esmat, G, Örmeci, N, Van, VH, Gschwantler, M, Akarca, U, Aleman, S, Balık, I, Berg, T, Bihl, F, Bilodeau, M, Blasco, AJ, Brandão, MCE, Bruggmann, P, Calinas, F, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cornberg, M, Cramp, ME, Dore, GJ, Doss, W, El-Sayed, MH, Ergör, G, Estes, C, Falconer, K, Félix, J, Ferraz, MLG, Ferreira, PR, García-Samaniego, J, Gerstoft, J, Giria, JA, Gonçales, FL, Guimarães, PM, Hézode, C, Hindman, SJ, Hofer, H, Husa, P, Idilman, R, Kåberg, M, Kaita, KDE, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Lázaro, P, Marinho, RT, Marotta, P, Mauss, S, Mendes, CMC, Moreno, C, Müllhaupt, B, Myers, RP, Nemecek, V, Øvrehus, ALH, Parkes, J, Peltekian, KM, Ramji, A, Razavi, H, Reis, N, Roberts, SK, Roudot-Thoraval, F, Ryder, SD, Sarmento-Castro, R, Sarrazin, C, Semela, D, Sherman, M, Shiha, GE, Sperl, J, Stärkel, P, Stauber, RE, Thompson, AJ, Urbanek, P, Van, DP, van, TI, Vandijck, D, Vogel, W, Waked, I & Wei 2014, 'Strategies to manage hepatitis C virus (HCV) disease burden.', J Viral Hepat, vol. 0, no. 0, pp. 60-89. https://doi.org/10.1111/jvh.12249

TY - JOUR

T1 - Strategies to manage hepatitis C virus (HCV) disease burden.

AU - Wedemeyer, H.

AU - Duberg, A. S.

AU - Buti, M.

AU - Rosenberg, W. M.

AU - Frankova, S.

AU - Esmat, G.

AU - Örmeci, N.

AU - Van, Vlierberghe H

AU - Gschwantler, M.

AU - Akarca, U.

AU - Aleman, S.

AU - Balık, I.

AU - Berg, T.

AU - Bihl, F.

AU - Bilodeau, M.

AU - Blasco, A. J.

AU - Brandão, Mello CE

AU - Bruggmann, P.

AU - Calinas, F.

AU - Calleja, J. L.

AU - Cheinquer, H.

AU - Christensen, P. B.

AU - Clausen, M.

AU - Coelho, H. S.M.

AU - Cornberg, M.

AU - Cramp, M. E.

AU - Dore, G. J.

AU - Doss, W.

AU - El-Sayed, M. H.

AU - Ergör, G.

AU - Estes, C.

AU - Falconer, K.

AU - Félix, J.

AU - Ferraz, M. L.G.

AU - Ferreira, P. R.

AU - García-Samaniego, J.

AU - Gerstoft, J.

AU - Giria, J. A.

AU - Gonçales, F. L.

AU - Guimarães, Pessôa M

AU - Hézode, C.

AU - Hindman, S. J.

AU - Hofer, H.

AU - Husa, P.

AU - Idilman, R.

AU - Kåberg, M.

AU - Kaita, K. D.E.

AU - Kautz, A.

AU - Kaymakoglu, S.

AU - Krajden, M.

AU - Krarup, H.

AU - Laleman, W.

AU - Lavanchy, D.

AU - Lázaro, P.

AU - Marinho, R. T.

AU - Marotta, P.

AU - Mauss, S.

AU - Mendes, Correa MC

AU - Moreno, C.

AU - Müllhaupt, B.

AU - Myers, R. P.

AU - Nemecek, V.

AU - Øvrehus, A. L.H.

AU - Parkes, J.

AU - Peltekian, K. M.

AU - Ramji, A.

AU - Razavi, H.

AU - Reis, N.

AU - Roberts, S. K.

AU - Roudot-Thoraval, F.

AU - Ryder, S. D.

AU - Sarmento-Castro, R.

AU - Sarrazin, C.

AU - Semela, D.

AU - Sherman, M.

AU - Shiha, G. E.

AU - Sperl, J.

AU - Stärkel, P.

AU - Stauber, R. E.

AU - Thompson, A. J.

AU - Urbanek, P.

AU - Van, Damme P

AU - van, Thiel I

AU - Vandijck, D.

AU - Vogel, W.

AU - Waked, I.

AU - Wei, null

PY - 2014/5

Y1 - 2014/5

N2 - The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.

AB - The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.

KW - HCV

KW - diagnosis

KW - disease burden

KW - epidemiology

KW - hepatitis C

KW - incidence

KW - mortality

KW - prevalence

KW - scenarios

KW - treatment

KW - Adolescent

KW - Adult

KW - Aged

KW - 80 and over

KW - Antiviral Agents

KW - Diagnostic Tests

KW - Routine

KW - Disease Eradication

KW - Drug Therapy

KW - Combination

KW - Female

KW - Global Health

KW - Hepatitis C

KW - Chronic

KW - Humans

KW - Incidence

KW - Male

KW - Middle Aged

KW - Models

KW - Statistical

KW - Prevalence

KW - Young Adult

U2 - 10.1111/jvh.12249

DO - 10.1111/jvh.12249

M3 - Article

SN - 1365-2893

VL - 0

SP - 60

EP - 89

JO - J Viral Hepat

JF - J Viral Hepat

IS - 0

ER -

Strategies to manage hepatitis C virus (HCV) disease burden.

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this